Redeye: Xspray Pharma Q1 2023 - First quarter of a transformative year
Redeye comments on Xspray Pharma following its Q1 2023 report. As a result of the report’s content, we slightly lower our base case but maintain our view that the ongoing lawsuit overshadows the case and see that current valuation is undemanding in relation to what is ahead of Xspray.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/